Discovery and Validation of Periodontitis Biomarkers

What this Trial Is About

Periodontitis is a significant public health concern in China, affecting millions of adults and leading to serious oral health problems such as loss of chewing function. The disease is expected to rise sharply by 2050, highlighting the need for coordinated actions including health education, AI-based self-detection tools, effective treatments, and healthcare system reorganization. Current diagnostic methods struggle to distinguish between early gingivitis and stage I periodontitis, limiting early intervention efforts. This research aims to discover new biomarkers to better understand and predict periodontitis onset and progression using advanced multi-omics techniques. The study will use a multi-omics approach including laser scanning microdissection proteomics, salivary proteomics, tissue transcriptomics, and microbiome analysis to identify distinct clusters within a mixed group of patients with gingivitis and stage I periodontitis. Participants will undergo diagnostic procedures including clinical measurements by a trained examiner and collection of various biological samples such as saliva, oral rinse, gingival fluid, subgingival microbiome samples, and tissue biopsies. These samples will be analyzed using state-of-the-art methods to discover biomarkers that may predict disease progression. Participants will be adults aged 18 to 40 diagnosed with different stages of periodontal disease. The study involves detailed clinical examinations and collection of biological samples stored for comprehensive analysis. Researchers will evaluate the accuracy of biomarker-defined clusters in predicting periodontitis progression over 24 months. The study is observational and aims to improve early detection methods. Participants’ health and cooperation will be monitored throughout the study period, which runs until October 2027.

Discovery and Validation of Periodontitis Biomarkers